BUZZ-Disc Medicine slips on planned stock sale
** Disc Medicine's shares down 1.9% to $59.35 premarket as biopharma firm looks to raise equity
** Watertown, Massachusetts-based firm late Tues $200 mln offering consisting of stock and pre-funded warrants
** Co plans to use net offering proceeds to fund research and clinical development of its product candidates, to support potential commercialization of its treatment for erythropoietic protoporphyria $(EPP.UK)$, a
rare disease that causes painful sensitivity to light
** IRON shares on Tues rose nearly 4% to close at $60.52 after co received from US FDA for
** Jefferies, Leerink, Stifel and Cantor jt bookrunners for the equity offering
** Through Tues, IRON shares down 4.5% to begin 2025. Stock's 1-yr high is $77.60 (Mar 4) and 1-yr low is $25.60 (Apr 1)
(Lance Tupper is a Reuters market analyst. The views expressed are his own) ((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available